Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2009-016267-11-FR
EUCTR2009-016267-11-FR
Active, not recruiting
Not Applicable

Etude des réponses immunitaires après vaccination anit-influenza saisonnier et anti-H1N1 variant pandémique dans une population de personnel soignant. - FLU-HOP

Inserm0 sitesOctober 5, 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionssymptome de la grippeMedDRA version: 12.0Level: LLTClassification code 10016797Term: Flu-like symptoms
DrugsVaxigrip

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
symptome de la grippe
Sponsor
Inserm
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 5, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Inserm

Eligibility Criteria

Inclusion Criteria

  • •\- Volontaires
  • •\- Age \= à 20 ans
  • •\- Pour les Femmes en age de procréer: sous contraception efficace (pilule ou stérilet)
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • •\- Immunodépression connue
  • •\- Prise de traitement immunomodulateur
  • •\- Femme enceinte (test de grossesse positif)
  • •\- Mère en cours d’allaitement
  • •\- Allergies ou hypersensibilité aux vaccins
  • •\- Maladies inflammatoires chroniques et maladies aiguës
  • •\- Participation à d’autres études cliniques

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VACThe vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.MedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisMedDRA version: 9.1Level: LLTClassification code 10046859Term: Vaccination
EUCTR2009-011523-31-GBR & D, Cambridge University Hospitals60
Active, not recruiting
Phase 1
Immunologiskt svar efter vaccinering med mRNA vaccin mot covid-19, Comirnaty, hos immunsupprimerade och immunkompetenta personer. En öppen icke randomiserad multicenterstudie i fas IV.SARS-COV-2 InfectionMedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2021-000175-37-SEKarolinska Universitetssjukhuset540
Completed
Phase 2
Study of HPV Vaccine adverse events and protection in patients with Juvenile Lupus and Juvenile Dermatomyositis
RBR-9ypbtfCoordenação de Aperfeiçoamento de Pessoal de Nível Superior
Recruiting
Not Applicable
CIMAvax-EGF in different maintenance schemeson small cell lung cancerNSCLCCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract Diseases
RPCEC00000368Center of Molecular Immunology (CIM)42
Recruiting
Not Applicable
Study on host immune response during treatment of patients with pulmonary nontuberculous mycobacterial diseasepulmonary nontuberculous mycobacterial disease
JPRN-UMIN000049658Department of Respiratory Medicine, University of Tsukuba100